Febrile Neutropenia Market Report 2026

Febrile Neutropenia Market Overview

• Febrile Neutropenia market size has reached to $11.28 billion in 2025 • Expected to grow to $15.19 billion in 2030 at a compound annual growth rate (CAGR) of 6.1% • Growth Driver: Rising Cancer Prevalence Fueling Growth In The Market • Market Trend: Advancement In Biosimilar Drugs For Febrile Neutropenia Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Febrile Neutropenia Market?

Febrile neutropenia is a medical condition characterized by a fever (temperature of 100.4°F or higher) and a low number of neutrophils, which are a type of white blood cell essential for fighting infections. This condition is often seen in patients undergoing chemotherapy or other treatments that suppress the immune system, making them more vulnerable to infections. The main treatment types of febrile neutropenia are empirical antibiotic therapy, targeted antibiotic therapy, and supportive care. Empirical antibiotic therapy involves starting treatment with broad-spectrum antibiotics based on clinical assessment prior to identifying the exact causative pathogen. It shows various risk factors such as chemotherapy-induced neutropenia, transplant-related neutropenia, and genetic disorders with several etiologies, including gram-negative bacteria, gram-positive bacteria, fungal infections, and viral infections. It is diagnosed by various diagnostic methods such as blood cultures, imaging tests, and bone marrow aspiration.

What Is The Febrile Neutropenia Market Growth Forecast?

The febrile neutropenia market size is expected to see strong growth in the next few years. It will grow to $15.19 billion in 2030 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to advancements in targeted antimicrobial therapy, growth in oncology patient population, improved early infection detection, rising use of G-CSFs, expansion of precision oncology care. Major trends in the forecast period include rising incidence of chemotherapy-induced neutropenia, increased use of empirical antibiotic therapy, growing adoption of supportive care treatments, expansion of hospital-based infection management, improved diagnostic and monitoring technologies.

Global Febrile Neutropenia Market Segmentation

1) By Treatment: Empirical Antibiotic Therapy, Targeted Antibiotic Therapy, Supportive Care 2) By Risk Factors: Chemotherapy-Induced Neutropenia, Transplant-Related Neutropenia, Genetic Disorders 3) By Etiology: Gram-Negative Bacteria, Gram-Positive Bacteria, Fungal Infections, Viral Infections 4) By Diagnostic Methods: Blood Cultures, Imaging Tests, Bone Marrow Aspiration Subsegments: 1) By Empirical Antibiotic Therapy: Broad-Spectrum Beta-Lactams, Glycopeptides, Carbapenems 2) By Targeted Antibiotic Therapy: Antifungal Therapy, Antiviral Therapy, Gram-Positive Bacterial Therapy, Gram-Negative Bacterial Therapy 3) By Supportive Care: Granulocyte Colony-Stimulating Factors (G-CSFs), Intravenous Fluids, Antipyretics And Pain Management

What Is The Driver Of The Febrile Neutropenia Market?

The increasing prevalence of cancer is expected to propel the growth of the febrile neutropenia market going forward. Cancer is a complex group of diseases characterized by the uncontrolled growth of abnormal cells that can invade surrounding tissues and spread to other parts of the body. The rising incidence of cancer is due to factors such as an aging population, environmental & occupational exposure, genetic predisposition, and hormonal & reproductive factors. Febrile neutropenia supports cancer patients by highlighting the heightened risk of infections during chemotherapy, prompting early intervention and targeted treatments to prevent life-threatening complications, thereby improving patient outcomes and enabling timely cancer therapy continuation. For instance, in 2024, according to the Canadian Cancer Society, a Canada-based national cancer charity, in 2024, in Canada, 32,100 people were diagnosed with lung cancer, accounting for 23.5% of all cancer-related deaths. Notably, lung cancer cases among females rose from 15,800 cases in 2023 to 17,300 cases in 2024. Therefore, the increasing prevalence of cancer is driving the growth of the febrile neutropenia industry.

Key Players In The Global Febrile Neutropenia Market

Major companies operating in the febrile neutropenia market are Pfizer Inc., Sanofi S.A., Amgen Inc., Teva Pharmaceutical Industries Ltd., Fresenius Kabi, Aurobindo Pharma Ltd., Lupin Limited, Hospira Inc., Coherus BioSciences Inc., Gennova Biopharmaceuticals Limited, Dr Reddy’s Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Novartis AG, Merck & Co. Inc., AstraZeneca PLC, Bayer AG, Cipla Ltd., Zydus Cadila, Celltrion Inc., Samsung Bioepis Co. Ltd.

Global Febrile Neutropenia Market Trends and Insights

Major companies operating in the febrile neutropenia market are focusing on developing advanced biosimilar drugs, such as long-acting granulocyte-colony stimulating factor (G-CSF) fusion proteins, to gain a competitive advantage. These fusion G-CSFs are recombinant proteins that link G-CSF to an Fc fragment, enabling sustained neutrophil stimulation over a chemotherapy cycle. For instance, in November 2024, Evive Biotech, a Singapore-based biopharmaceutical company, introduced in Germany a non-pegylated long-acting G-CSF designed for chemotherapy-induced neutropenia, offering an extended half-life via an IgG2-Fc fusion and mammalian cell expression for human-like glycosylation. These next-generation and biosimilar G-CSFs improve patient access and reduce dosing frequency, though they face regulatory complexity and potential immunogenicity concerns.

What Are Latest Mergers And Acquisitions In The Febrile Neutropenia Market?

In July 2023, Assertio Holdings Inc., a US-based pharmaceutical company, acquired Spectrum Pharmaceuticals for an undisclosed amount. The acquisition aims to expand and diversify Assertio’s revenue base, enhance its oncology portfolio with ROLVEDON (eflapegrastim-xnst) injection, and strengthen its commercial and digital marketing capabilities. Spectrum Pharmaceuticals is a US-based pharmaceutical company that manufactures febrile neutropenia drugs.

Regional Outlook

North America was the largest region in the febrile neutropenia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Febrile Neutropenia Market?

The febrile neutropenia market consists of revenues earned by entities by providing services such as diagnostic services, hematologic support, hospitalization and monitoring, and outpatient management. The market value includes the value of related goods sold by the service provider or included within the service offering. The febrile neutropenia market also includes sales of antibiotics, antifungal and antiviral medications, urinalysis, and urine culture. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Febrile Neutropenia Market Report 2026?

The febrile neutropenia market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the febrile neutropenia industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.